8-K: Masimo Reports Strong Preliminary 2025 Results

Masimo Corporation announced preliminary Q4 and full-year 2025 financial results, showing robust revenue growth and non-GAAP EPS at the high end of guidance.

Summary

• Preliminary fourth quarter 2025 revenue is expected to be approximately $411 million, representing approximately 12% growth on a reported basis and 11% growth on a constant currency basis.
• Preliminary fourth quarter 2025 non-GAAP earnings per diluted share, including the impact of new tariffs, are expected to be more than $1.54.
• Preliminary fourth quarter 2025 shipments of noninvasive technology boards and instruments are expected to be approximately 69 thousand.
• Preliminary full-year 2025 revenue is expected to be approximately $1,523 million, representing approximately 9% growth on a reported basis and constant currency basis.
• Preliminary full-year 2025 non-GAAP earnings per diluted share, including the impact of new tariffs, are expected to be more than $5.55, which represents the high end of the company's guidance range.
• Preliminary full-year 2025 shipments of noninvasive technology boards and instruments are expected to be approximately 270 thousand.
• Complete fourth quarter and full-year 2025 financial results, along with full-year 2026 guidance, will be discussed after the market closes on Thursday, February 26, 2026.

Sentiment

Score: 8

Explanation: The filing presents strong preliminary financial results, with full-year non-GAAP EPS at the high end of guidance, and outlines an ambitious long-range plan with significant growth targets and a robust product pipeline.

Positives

• Strong preliminary financial results for both Q4 and full-year 2025, demonstrating continued execution of strategy.
• Full-year 2025 non-GAAP EPS is expected to exceed $5.55, reaching the high end of the company's guidance range.
• Achieved a record level of incremental contract value from new customers in 2025.
• Expanded hospital agreements with existing customers, positioning the company well for sustained performance.
• Long-range plan targets through 2028 include a 7-10% Revenue CAGR, Adjusted EPS of over $8.00, approximately $1 billion in cumulative operating cash flow, and an operating margin of around 30%.
• Maintains a resilient global supply chain and a leading monitoring portfolio with over 80% recurring revenue.
• Boasts a large and growing installed base of approximately 2.6 million technology boards and monitors with a 98%+ renewal rate.
• Secured a new multi-year partnership renewal with Philips, creating an equivalent share gain opportunity.
• Masimo SET Pulse Oximetry is recognized as #1, used on over 200 million patients annually and is the primary pulse oximetry at all 10 top U.S. hospitals.
• A meaningful pipeline of innovations is planned, including next-gen Root, Patient SafetyNet, and new algorithms for Sepsis, OIRD, AFib, and Predictive Respiratory Depression, with launches extending through 2028 and beyond.

Negatives

• New tariffs are impacting non-GAAP earnings per diluted share.
• Revenue was lost from discontinued product lines at the end of 2024.
• The company is shifting to a distributor model in some international markets, which may have transitional impacts.
• The implementation of tariffs remains a dynamic and uncertain situation that could cause actual results to be materially different from projections and forecasts.

Risks

• Dependence on Masimo SET and Masimo rainbow SET products and technologies for substantially all revenue.
• Any failure in protecting intellectual property.
• Exposure to competitors' assertions of intellectual property claims.
• The highly competitive nature of the markets in which products and technologies are sold.
• Any failure to continue developing innovative products and technologies.
• Lack of acceptance of any current or future products and technologies.
• Challenges in obtaining regulatory approval of current and future products and technologies.
• The risk that the implementation of international realignment will not continue to produce anticipated operational and financial benefits, including a continued lower effective tax rate.
• The loss of customers.
• Matters relating to future board and management leadership.
• Product liability claims exposure.
• The amount and type of equity awards that may be granted to employees and service providers in the future.
• Ongoing litigation and related matters, specifically with Apple.
• Evolving legal, regulatory, and tax regimes.
• Changes in general economic and/or industry-specific conditions.
• Actions by third parties, including government agencies.
• Impact of tariffs.

Future Outlook

Masimo's long-range plan targets through 2028 include a 7-10% revenue CAGR, adjusted EPS of over $8.00, approximately $1 billion in cumulative operating cash flow, and an operating margin of around 30%. The company plans to accelerate growth through new product introductions, focusing on elevating commercial excellence, increasing US and international pulse oximetry market share, expanding advanced monitoring, and executing new product launches. Key upcoming innovations include next-gen Root, Patient SafetyNet, and new algorithms for conditions like Sepsis, OIRD, AFib, and Predictive Respiratory Depression.

Management Comments

• "Our strong performance this quarter reflects the continued execution of our strategy and the value our solutions deliver for customers."
• "In 2025, we achieved a record level of incremental contract value from new customers and expanded hospital agreements with our existing customers, which positions us well for sustained performance in the year ahead." (Katie Szyman, Chief Executive Officer)

Industry Context

Masimo operates in the highly competitive medical technology and patient monitoring industry. It positions itself as a global leader, particularly in pulse oximetry, with its SET technology used in over 150 countries and by all top 10 U.S. hospitals. The company sees significant market opportunities in US Pulse Ox (~$1.5B market, ~45% opportunity), International Pulse Ox (~$800M market, ~65% opportunity), Advanced Monitoring (~$2.5B market, ~85% opportunity), and Continuous Monitoring (~$2B TAM, ~98%+ opportunity), indicating ample room for market share capture and expansion.

Comparison to Industry Standards

• Masimo SET Pulse Oximetry is #1, recognized for best-in-class accuracy in motion and low perfusion, used on over 200 million patients globally, and adopted by all top 10 US hospitals.
• CO-Oximetry* & Hemodynamics, Capnography, and SedLine + O3 Brain Monitoring are ranked #2 in their respective market segments.
• The company boasts a 98%+ customer retention rate over the past 10 years and a ~90% win-rate during head-to-head clinical evaluations, demonstrating strong competitive performance.
• Real-world evidence shows Masimo Pulse Ox leads to a 50% reduction in unplanned ICU transfers, 80% reduction in ROP, 86% fewer false alarms, and 60% reduction in rapid response team activations, and has been shown to reduce costs.
• The new Philips partnership is highlighted as an equivalent share gain opportunity, indicating a strong competitive position against major industry players.

Management Changes

Corporate Governance

Legal Proceedings

• Engaged in various legal proceedings against Apple since January 2020, including federal courts, U.S. Patent and Trademark Office (PTO proceedings), and a U.S. International Trade Commission (ITC proceeding).

Stakeholder Impact

• Shareholders are likely to view the strong preliminary financial results, high-end EPS guidance, and ambitious long-range growth targets positively, potentially leading to increased share value.
• Customers will continue to benefit from Masimo's 'winning portfolio of market-leading innovations' and high customer retention rates, with new product launches promising enhanced patient monitoring and safety solutions.
• Employees may experience opportunities for growth and innovation, but also potential implications from 'business transition plans' which could include severance and relocation costs.
• Suppliers can expect continued demand for components and services given the company's growth and robust product pipeline.
• Creditors will likely view the strong financial performance and positive cash flow targets as indicators of good creditworthiness.

Next Steps

• Management plans to discuss complete fourth quarter and full-year 2025 financial results after the market closes on Thursday, February 26, 2026.
• Full-year 2026 guidance will also be provided on February 26, 2026.
• Multi-year launch of new Pulse Ox sensors begins in 2026.
• Upcoming product launches and algorithm additions through 2028 and beyond.

Key Dates

Recommendation

The preliminary results indicate robust performance, with full-year non-GAAP EPS hitting the high end of guidance, demonstrating strong execution despite tariff impacts. The outlined long-range plan through 2028 projects significant revenue growth, EPS expansion, and substantial operating cash flow, supported by a strong product pipeline and strategic commercial initiatives. Masimo's market leadership, high customer retention, and continuous innovation in critical patient monitoring technologies position it for sustained long-term growth, making it an attractive investment.

Keywords

Masimo, MASI, financial results, preliminary results, Q4 2025, full-year 2025, revenue, EPS, non-GAAP, medical technology, patient monitoring, pulse oximetry, healthcare, tariffs, corporate governance, J.P. Morgan Healthcare Conference, SEC filing, 8-K